• FDA Approves Risankizumab for Psoriatic Arthritis

    4 monthes ago - By Medscape

    The approval is the second indication for the anti-interleukin 23 monoclonal antibody after approval for plaque psoriasis was granted in 2019.
    Medscape Medical News
    Read more ...

     

  • FDA approves Skyrizi for adults with active psoriatic arthritis

    FDA approves Skyrizi for adults with active psoriatic arthritis

    4 monthes ago - By Healio

    The FDA has approved AbbVie's risankizumab-rzaa for the treatment of adults with active psoriatic arthritis, expanding its initial indication from plaque psoriasis only.
    Risankizumab , an interleukin-23 inhibitor, made its U.S. debut in 2019 for moderate-to-severe plaque psoriasis among adults who are candidates for systemic therapy or phototherapy. The new approval for PsA follows results from the KEEPsAKE 1 and KEEPsAKE 2 trials, both of which resulted in statistically greater improvements in signs and symptoms, relative to placebo, among patients
    Read more ...